Nadia Waheed - Feb 11, 2025 Form 4 Insider Report for OCULAR THERAPEUTIX, INC (OCUL)

Role
Chief Medical Officer
Signature
/s/ Donald Notman, Attorney-in-Fact for Nadia Waheed
Stock symbol
OCUL
Transactions as of
Feb 11, 2025
Transactions value $
$0
Form type
4
Date filed
2/13/2025, 08:37 PM
Previous filing
Jun 4, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OCUL Common Stock Award $0 +79K +55.76% $0.00 221K Feb 11, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCUL Stock Option (Right to Buy) Award $0 +237K $0.00 237K Feb 11, 2025 Common Stock 237K $7.44 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 11, 2025, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter.
F2 Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant.